164 related articles for article (PubMed ID: 38340635)
1. Constructing "smart" chelators by using an activatable prochelator strategy for the treatment of Wilson's disease.
Wang C; Wang R; Zhao L; Wang S; Liu Y; Zhao J; Dong Y; Liu L; Wei P; Wu ZY; Yi T
Redox Biol; 2024 Apr; 70():103076. PubMed ID: 38340635
[TBL] [Abstract][Full Text] [Related]
2. DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson's disease.
Krishnan N; Felice C; Rivera K; Pappin DJ; Tonks NK
Genes Dev; 2018 Jul; 32(13-14):944-952. PubMed ID: 29945887
[TBL] [Abstract][Full Text] [Related]
3. Wilson's disease: A 2017 update.
Poujois A; Woimant F
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):512-520. PubMed ID: 29625923
[TBL] [Abstract][Full Text] [Related]
4. ARBM101 (Methanobactin SB2) Drains Excess Liver Copper via Biliary Excretion in Wilson's Disease Rats.
Einer C; Munk DE; Park E; Akdogan B; Nagel J; Lichtmannegger J; Eberhagen C; Rieder T; Vendelbo MH; Michalke B; Wimmer R; Blutke A; Feuchtinger A; Dershwitz P; DiSpirito AM; Islam T; Castro RE; Min BK; Kim T; Choi S; Kim D; Jung C; Lee H; Park D; Im W; Eun SY; Cho YH; Semrau JD; Rodrigues CMP; Hohenester S; Damgaard Sandahl T; DiSpirito AA; Zischka H
Gastroenterology; 2023 Jul; 165(1):187-200.e7. PubMed ID: 36966941
[TBL] [Abstract][Full Text] [Related]
5. Chelation therapy in Wilson's disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators.
Delangle P; Mintz E
Dalton Trans; 2012 Jun; 41(21):6359-70. PubMed ID: 22327203
[TBL] [Abstract][Full Text] [Related]
6. [The onset of psychiatric disorders and Wilson's disease].
Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
[TBL] [Abstract][Full Text] [Related]
7. Development, formulation, and cellular mechanism of a lipophilic copper chelator for the treatment of Wilson's disease.
Gauthier L; Charbonnier P; Chevallet M; Delangle P; Texier I; Gateau C; Deniaud A
Int J Pharm; 2021 Nov; 609():121193. PubMed ID: 34673167
[TBL] [Abstract][Full Text] [Related]
8. Design of intrahepatocyte copper(I) chelators as drug candidates for Wilson's disease.
Gateau C; Delangle P
Ann N Y Acad Sci; 2014 May; 1315():30-6. PubMed ID: 24611802
[TBL] [Abstract][Full Text] [Related]
9. Wilson's disease: clinical, genetic and pharmacological findings.
Leggio L; Addolorato G; Abenavoli L; Gasbarrini G
Int J Immunopathol Pharmacol; 2005; 18(1):7-14. PubMed ID: 15698506
[TBL] [Abstract][Full Text] [Related]
10. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
11. [Pathogenesis and treatment of Wilson's disease].
Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
[TBL] [Abstract][Full Text] [Related]
12. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice.
Hoogenraad TU
Brain Dev; 2006 Apr; 28(3):141-6. PubMed ID: 16466879
[TBL] [Abstract][Full Text] [Related]
13. Wilson's disease: overview.
Lucena-Valera A; Ruz-Zafra P; Ampuero J
Med Clin (Barc); 2023 Mar; 160(6):261-267. PubMed ID: 36697289
[TBL] [Abstract][Full Text] [Related]
14. Pathological mitochondrial copper overload in livers of Wilson's disease patients and related animal models.
Zischka H; Lichtmannegger J
Ann N Y Acad Sci; 2014 May; 1315():6-15. PubMed ID: 24517326
[TBL] [Abstract][Full Text] [Related]
15. Demonstrating Potential of Cell Therapy for Wilson's Disease with the Long-Evans Cinnamon Rat Model.
Jaber FL; Sharma Y; Gupta S
Methods Mol Biol; 2017; 1506():161-178. PubMed ID: 27830552
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and outcome of Wilson's disease with generalized epilepsy in Chinese patients.
Wang RM; Yu H; Yang GM; Xu WQ; Xia N; Zhang Y; Ni W; Dong Y; Wu ZY
CNS Neurosci Ther; 2020 Aug; 26(8):842-850. PubMed ID: 32281751
[TBL] [Abstract][Full Text] [Related]
17. The link between copper and Wilson's disease.
Purchase R
Sci Prog; 2013; 96(Pt 3):213-23. PubMed ID: 24244969
[TBL] [Abstract][Full Text] [Related]
18. Biopolymer strategy for the treatment of Wilson's disease.
Vetrik M; Mattova J; Mackova H; Kucka J; Pouckova P; Kukackova O; Brus J; Eigner-Henke S; Sedlacek O; Sefc L; Stepanek P; Hruby M
J Control Release; 2018 Mar; 273():131-138. PubMed ID: 29407674
[TBL] [Abstract][Full Text] [Related]
19. The treatment of Wilson's disease, a rare genetic disorder of copper metabolism.
Purchase R
Sci Prog; 2013; 96(Pt 1):19-32. PubMed ID: 23738435
[TBL] [Abstract][Full Text] [Related]
20. Axonal sensory motor neuropathy in copper-deficient Wilson's disease.
Foubert-Samier A; Kazadi A; Rouanet M; Vital A; Lagueny A; Tison F; Meissner W
Muscle Nerve; 2009 Aug; 40(2):294-6. PubMed ID: 19609919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
